Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The centralized marketing authorization granted by the EC is valid in all EU Member
Subscribe To Our Newsletter & Stay Updated
